Recent trends on dydrogesterone in gynaecology, obstetrics, and infertility: insights from Indian experts
DOI:
https://doi.org/10.18203/2320-1770.ijrcog20243224Keywords:
Dydrogesterone, Infertility, Endometriosis, RPL, PCOS, Gynaecology and obstetricsAbstract
Infertility affects millions globally, with significant prevalence in India due to conditions like endometriosis and polycystic ovarian syndrome (PCOS). Dydrogesterone, a synthetic progesterone, has demonstrated efficacy in managing endometriosis, recurrent pregnancy loss (RPL), and infertility. Endometriosis, affecting 10% of reproductive-aged women, often leads to infertility and recurrent pain despite surgical interventions. Dydrogesterone 20 mg effectively reduces chronic pelvic pain and improves quality of life in these patients. In infertility management, dydrogesterone enhances luteal phase support (LPS), leading to higher pregnancy rates and better reproductive outcomes compared to other progesterone forms. It is particularly beneficial in in vitro fertilization (IVF) and intrauterine insemination (IUI) cycles, showing improved patient compliance and reduced side effects. For RPL, dydrogesterone stabilizes the endometrial environment, supporting implantation and early embryonic development. Its use in PCOS aids in menstrual regulation and pregnancy preparation without inhibiting ovulation. Expert opinions from Indian gynaecologists highlight the need for tailored dydrogesterone protocols to address the unique challenges in Indian healthcare. This document gathers insights from these experts, emphasizing the therapeutic potential of dydrogesterone in gynaecology, obstetrics, and infertility management.
Metrics
References
Katole A, Saoji AV. Prevalence of Primary Infertility and its Associated Risk Factors in Urban Population of Central India: A Community-Based Cross-Sectional Study. Indian J Community Med Off Publ Indian Assoc Prev Soc Med. 2019;44(4):337-41.
Moradi Y, Shams-Beyranvand M, Khateri S, Gharahjeh S, Tehrani S, Varse F, et al. A systematic review on the prevalence of endometriosis in women. Indian J Med Res. 2021;154(3):446-54.
Rozati R, Tabasum W, Ahmed MS, Khan AA, Ahmed TN, Nayela S, et al. Prevalence, Surgical, and Medical Management of Patients with Endometriosis amongst Indian Women. Eur J Med Health Sci. 2023;5(6):101-6.
Bulletti C, Coccia ME, Battistoni S, Borini A. Endometriosis and infertility. J Assist Reprod Genet. 2010;27(8):441-7.
Boje AD, Egerup P, Westergaard D, Bertelsen MLMF, Nyegaard M, Hartwell D, et al. Endometriosis is associated with pregnancy loss: a nationwide historical cohort study. Fertil Steril. 2023;119(5):826-35.
Cohain JS, Buxbaum RE, Mankuta D. Spontaneous first trimester miscarriage rates per woman among parous women with 1 or more pregnancies of 24 weeks or more. BMC Pregnancy Childbirth. 2017;17(1):437.
Polycystic Ovarian Syndrome (PCOS) and its Complications. Available at: https://pib.gov.in/pib.gov.in/Pressreleaseshare.aspx?PRID=1893279. Accessed on 10 June 2024.
Endometriosis. Available at: https://www.acog.org/womens-health/faqs/endometriosis. Accessed on 31 May 2024.
Bashiri A, Galperin G, Zeadna A, Baumfeld Y, Wainstock T. Increased Live Birth Rate with Dydrogesterone among Patients with Recurrent Pregnancy Loss Regardless of Other Treatments. J Clin Med. 2023;12(5):1967.
Ford HB, Schust DJ. Recurrent Pregnancy Loss: Etiology, Diagnosis, and Therapy. Rev Obstet Gynecol. 2009;2(2):76-83.
Mechsner S. Endometriosis, an Ongoing Pain-Step-by-Step Treatment. J Clin Med. 2022;11(2):10.
Peng C, Huang Y, Zhou Y. Dydrogesterone in the treatment of endometriosis: evidence mapping and meta-analysis. Arch Gynecol Obstet. 2021;304(1):231-52.
Sukhikh GT, Adamyan LV, Dubrovina SO, Baranov II, Bezhenar VF, Kozachenko AV, et al. Prolonged cyclical and continuous regimens of dydrogesterone are effective for reducing chronic pelvic pain in women with endometriosis: results of the ORCHIDEA study. Fertil Steril. 2021;116(6):1568-77.
Liu Y, Yu X, Huang J, Du C, Zhou H, Yang Y, et al. Additional dydrogesterone for the treatment of chronic endometritis treated with antibiotic in premenopausal women with endometrial polyps: a retrospective cohort study. BMC Womens Health. 2022;22:435.
Muneeba S, Acharya N, Mohammad S. The Role of Dydrogesterone in the Management of Luteal Phase Defect: A Comprehensive Review. Cureus. 2024;15(11):e48194.
Griesinger G, Blockeel C, Kahler E, Pexman-Fieth C, Olofsson JI, Driessen S, et al. Dydrogesterone as an oral alternative to vaginal progesterone for IVF luteal phase support: A systematic review and individual participant data meta-analysis. PLoS ONE. 2020;15(11):e0241044.
Khosravi D, Taheripanah R, Taheripanah A, Tarighat Monfared V, Hosseini-Zijoud SM. Comparison of oral dydrogesterone with vaginal progesteronefor luteal support in IUI cycles: a randomized clinical trial. Iran J Reprod Med. 2015;13(7):433-8.
Vidal A, Dhakal C, Werth N, Weiss JM, Lehnick D, Kohl Schwartz AS. Supplementary dydrogesterone is beneficial as luteal phase support in artificial frozen-thawed embryo transfer cycles compared to micronized progesterone alone. Front Endocrinol. 2023;14.
Vuong LN, Pham TD, Le KTQ, Ly TT, Le HL, Nguyen DTN, et al. Micronized progesterone plus dydrogesterone versus micronized progesterone alone for luteal phase support in frozen-thawed cycles (MIDRONE): a prospective cohort study. Hum Reprod Oxf Engl. 2021;36(7):1821-31.
Metello J, Tomas C, Ferreira P, Santos-Ribeiro S. The Addition of Dydrogesterone after Frozen Embryo Transfer in Hormonal Substituted Cycles with Low Progesterone Levels. RBGO Gynecol Obstet. 2022;44(10):930.
I.S.A.R - Indian Society For Assisted Reproduction. Available at: https://www.isarindia.net/. Accessed on 14 June 2024.
Recurrent pregnancy loss. Available at: https://www.eshre.eu/Guidelines-and-Legal/Guidelines/Recurrent-pregnancy-loss. Accessed on 14 June 2024.
Omar MH, Mashita MK, Lim PS, Jamil MA. Dydrogesterone in threatened abortion: Pregnancy outcome. J Steroid Biochem Mol Biol. 2005;97(5):421-5.
Nagarkatti R, Mehra D, Mandal S, Dhawan A, Joshi P, Nagarkatti N, et al. Real-world evaluation of safety and effectiveness of dydrogesterone in the management of threatened abortion. Int J Reprod Contracept Obstet Gynecol. 2022;11(8):2096.
Expert Group of Consensus on Infertility Management and Fertility Preservation Related to Polycystic Ovary Syndrome, Reproductive Endocrinology and Fertility Preservation Section of Chinese Society on Fertility Preservation under Chinese Preventive Medicine Association, Tian QJ. Consensus on Infertility Management and Fertility Preservation Related to Polycystic Ovary Syndrome. Reprod Dev Med. 2020;04(04):241-50.
Gurbuz AS, Gode F. Dydrogesterone-primed ovarian stimulation is an effective alternative to gonadotropin-releasing hormone antagonist protocol for freeze-all cycles in polycystic ovary syndrome. J Obstet Gynaecol Res. 2020;46(8):1403-11.
Recommendations from the 2023 International Evidence-based Guideline for the Assessment and Management of Polycystic Ovary Syndrome (2023). Available at: https://www.asrm.org/practice-guidance/practice-committee-documents/recommendations-from-the-2023-international-evidence-based-guideline-for-the-assessment-and-management-of-polycystic-ovary-syndrome/. Accessed on 14 June 2024.
Thongchan S, Phupong V. Oral dydrogesterone as an adjunctive therapy in the management of preterm labor: a randomized, double blinded, placebo‐controlled trial. BMC Pregnancy Childbirth. 2021;21(1):90.
Hudic I, Schindler AE, Szekeres-Bartho J, Stray-Pedersen B. Dydrogesterone and pre-term birth. Horm Mol Biol Clin Investig. 2016;27(3):81-3.
Mueck AO, Seeger H, Bühling KJ. Use of dydrogesterone in hormone replacement therapy. Maturitas. 2009;65(1):S51-60.
Downloads
Published
How to Cite
Issue
Section
